Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase

Journal of Investigative Dermatology

Volumn 131, Issue 12, 2011, Pages 2448-2457

  Sensi, Marialuisa ^a   Catani, Mara ^a,c   Castellano, Giancarlo ^a,d   Nicolini, Gabriella ^a   Alciato, Federica ^b   Tragni, Gabrina ^a   De Santis, Giuseppina ^a   Bersani, Ilaria ^a   Avanzi, Giancarlo ^b   Tomassetti, Antonella ^a   Canevari, Silvana ^a   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d Parc Recerca Biomèdica de Barcelona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AXL RECEPTOR KINASE; DIFFERENTIATION ANTIGEN; GLYCOPROTEIN GP 100; GROWTH ARREST SPECIFIC PROTEIN 6; MELAN A; MELANOCYTE DIFFERENTIATION ANTIGEN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; CELL INVASION; CELL MATURATION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; PIGMENTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 80855138159     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.218     Document Type: Article

References (38)

1. Alciato F, Sainaghi PP, Castello L et al (2008) Development and validation of an ELISA method for detection of growth arrest specific 6 (GAS6) protein in human plasma. J Immunoassay Immunochem 29:167-80 (Pubitemid 351431254)
2. Anichini A, Mortarini R, Maccalli C et al. (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156: 208-17 (Pubitemid 26006965)
3. Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-40 (Pubitemid 30625740)
4. Carreira S, Goodall J, Denat L et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20:3426-39 (Pubitemid 44969160)
5. Curtin JA, Busam K, Pinkel D et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6 (Pubitemid 46630793)
6. Daniotti M, Oggionni M, Ranzani T et al. (2004) BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23:5968-77 (Pubitemid 39093541)
7. De Santis G, Miotti S, Mazzi M et al. (2009) E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene 28: 1206-17
8. Gjerdrum C, Tiron C, Hoiby T et al. (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107:1124-9
9. Graeber TG, Eisenberg D (2001) Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles. Nat Genet 29:295-300 (Pubitemid 33096454)
10. Hoek KS, Eichhoff OM, Schlegel NC et al. (2008a) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68:650-6 (Pubitemid 351206739)
11. Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23:746-59
12. Hoek KS, Schlegel NC, Brafford P et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19:290-302 (Pubitemid 44015592)
13. Hoek KS, Schlegel NC, Eichhoff OM et al. (2008b) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21:665-76
14. Holland SJ, Pan A, Franci C et al. (2010) R428, a selective small molecule inhibitor of Axl kinase blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70:1544-54
15. Holland SJ, Powell MJ, Franci C et al. (2005) Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 65:9294-303 (Pubitemid 41507996)
16. Jeffs AR, Glover AC, Slobbe LJ et al. (2009) A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4:e8461
17. Johannessen CM, Boehm JS, Kim SY et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72
18. Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histologic types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164:776-84
19. Linger RM, Keating AK, Earp HS et al. (2010) Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14:1073-90
20. Mitra D, Fisher DE (2009) Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 23:447-65, viii
21. O'Bryan JP, Frye RA, Cogswell PC et al. (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11:5016-31 (Pubitemid 21895263)
22. Palavalli LH, Prickett TD, Wunderlich JR et al. (2009) Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41:518-20
23. Pavey S, Johansson P, Packer L et al. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-7 (Pubitemid 38747936)
24. Pleasance ED, Cheetham RK, Stephens PJ et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-6
25. Prickett TD, Agrawal NS, Wei X et al. (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127-32
26. Quong RY, Bickford ST, Ing YL et al. (1994) Protein kinases in normal and transformed melanocytes. Melanoma Res 4:313-9 (Pubitemid 24323266)
27. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101-8 (Pubitemid 351818697)
28. Segura MF, Hanniford D, Menendez S et al. (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106:1814-9
29. Sensi M, Nicolini G, Zanon M et al. (2005) Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res 65:632-40
30. Sensi M, Pietra G, Molla A et al. (2009) Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Int Immunol 21:257-68
31. Tai KY, Shieh YS, Lee CS et al. (2008) Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 3:4044-55
32. Van Ginkel PR, Gee RL, Shearer RL et al. (2004) Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 64:128-34 (Pubitemid 38114090)
33. Varnum BC, Young C, Elliott G et al. (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373:623-6
34. Wagle N, Emry C, Berger MF et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol; e-pub ahead of print 7 March 2011
35. Wagner KW, Punnoose EA, Januario T et al. (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13:1070-7 (Pubitemid 47517508)
36. Ye X, Li Y, Stawicki S et al. (2010) Anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29:5254-64
37. Zendman AJ, Ruiter DJ, Van Muijen GN (2003) Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 194:272-88 (Pubitemid 36176890)
38. Zhu S, Wurdak H, Wang Y et al. (2009) A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci USA 106: 17025-30